BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Issues Shareholder Letter, Corporate Update

February 1, 2021 15:28:47

Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, has issued a shareholder letter and corporate update outlining its developments and initiatives for 2020 and anticipated milestones for 2021 and beyond. “We achieved many significant milestones in 2020 that have set the stage for a transformational 2021,” stated Rodney Varner, president and CEO of Genprex. “The primary focus this past year was on the preparation for our two lead clinical trials in non-small cell lung cancer (‘NSCLC’). Our Acclaim-1 clinical trial will combine REQORSA with Tagrisso(R) for patients with late stage NSCLC whose disease progressed after treatment with Tagrisso. Our Acclaim-2 clinical trial will combine REQORSA with Keytruda(R) for NSCLC patients who are low expressors (1% to 49%) of the protein programmed death-ligand 1 (‘PD-L1’). We remain on track to initiate both trials in the first-half of 2021. Additionally, the $40 million-plus in capital infusions in 2020 provided us with a strong balance sheet as 2021 begins. We are grateful for the confidence and support of our shareholders and look forward to executing on our strategies to achieve a number of potentially value-creating milestones.”

To view the full press release, visit

About Genprex Inc.

Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, “REQORSA(TM)” (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. For more information, visit the company’s web site at

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork